EDMONTON, Oct. 12 /CNW/ - BioMS Medical Corp (TSX: MS - News), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the National Agency for Medicines to begin enrolling patients in Finland into its ongoing pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
